Neglected Tropical Disease Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14357701 | Publishing Date : 10-Jun-2019 | No. of pages : 120
Detailed TOC of Neglected Tropical Disease Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Antiparasitic drugs - Market size and forecast 2018-2023
Antibacterial drugs - Market size and forecast 2018-2023
Antiviral drugs - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
ROW - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
North America - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Market trends
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bayer AG
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Diseases caused by organisms
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antiparasitic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antiparasitic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antibacterial drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antibacterial drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antiviral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antiviral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer AG - Vendor overview
Exhibit 45: Bayer AG - Business segments
Exhibit 46: Bayer AG - Organizational developments
Exhibit 47: Bayer AG - Geographic focus
Exhibit 48: Bayer AG - Segment focus
Exhibit 49: Bayer AG - Key offerings
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: Novartis AG - Vendor overview
Exhibit 63: Novartis AG - Business segments
Exhibit 64: Novartis AG - Organizational developments
Exhibit 65: Novartis AG - Geographic focus
Exhibit 66: Novartis AG - Segment focus
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Pfizer Inc. - Vendor overview
Exhibit 69: Pfizer Inc. - Business segments
Exhibit 70: Pfizer Inc. - Organizational developments
Exhibit 71: Pfizer Inc. - Geographic focus
Exhibit 72: Pfizer Inc. - Segment focus
Exhibit 73: Pfizer Inc. - Key offerings
Exhibit 74: Validation techniques employed for market sizing
Exhibit 75: Definition of market positioning of vendors
Keyplayers in Neglected Tropical Disease Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
Bayer AGF. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.